Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | PLK1 | P53350 | 5/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19541913 | 1.00 | GLP1R (0.45) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL16329597 | 1.00 | GLP1R (0.45) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL22025537 | 1.00 | GLP1R (0.45) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL16329598 | 1.00 | GLP1R (0.45) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL16329593 | 0.99 | GLP1R (0.45) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL16329692 | 0.96 | GLP1R (0.44) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL16329543 | 0.95 | PLK1 (0.47) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL22514355 | 0.94 | GLP1R (0.41) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL22026131 | 0.94 | GLP1R (0.42) | GLP1RPLK1AKT1TLR2TLR1 | |
| SCHEMBL19541915 | 0.94 | GLP1R (0.42) | GLP1RPLK1AKT1TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | BTD, IDUA, DNPEP | GLP1R 647/4885PLK1 1197/4885AKT1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.